US3687971A - 4-(pyrrolyl)-salicylic acid derivatives - Google Patents

4-(pyrrolyl)-salicylic acid derivatives Download PDF

Info

Publication number
US3687971A
US3687971A US48479A US3687971DA US3687971A US 3687971 A US3687971 A US 3687971A US 48479 A US48479 A US 48479A US 3687971D A US3687971D A US 3687971DA US 3687971 A US3687971 A US 3687971A
Authority
US
United States
Prior art keywords
gms
salicylic acid
mixture
pyrrolyl
thiazolyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US48479A
Inventor
Tsung-Ying Shen
Howard Jones
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of US3687971A publication Critical patent/US3687971A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C07D207/327—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C331/00—Derivatives of thiocyanic acid or of isothiocyanic acid
    • C07C331/02—Thiocyanates
    • C07C331/10—Thiocyanates having sulfur atoms of thiocyanate groups bound to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Definitions

  • the new 4-(hetero cyclic)salicyclic acid compounds described have antiinflammatory, anti-pyretic and analgesic activity.
  • This invention relates to new heterocyclic phenyl compounds and to processes for producing the same. More specifically, it relates to 4-(heterocyclic)-salicylic acid compounds (2-hdroxy -4-heterocyclic benzoic acids). Still more specifically, this invention relates to compounds having the following general formula:
  • Het is a 6- membered ring structure containing from one to three hetero atoms or a five-membered ring structure containing from one to four hetero atoms.
  • the hetero atoms are either nitrogen, sulphur, or oxygen;
  • R is hydrogen, lower alkyl, lower alkoxy, halogen, or
  • R is hydrogen, alkyl (preferably lower alkyl, such as methyl, ethyl, propyl, isopropyl, butyl or pentyl), halo (such as, chlorine, bromine or iodine or fluorine), amino, alkyl amino, (preferably lower alkyl amino, such as methyl amino or isopropyl amino), dialkyl amino, (preferably diloweralkyl amino such as dimethyl amino or diethyl amino), hydroxy or alkoxy (preferably lower alkoxy, such as methoxy or ethoxy).
  • alkyl preferably lower alkyl, such as methyl, ethyl, propyl, isopropyl, butyl or pentyl
  • halo such as, chlorine, bromine or iodine or fluorine
  • dialkyl amino preferably diloweralkyl amino such as di
  • the six-membered ring structure containing from one to three hetero atoms are 2,3 or 4-pyridyl, 2 or 3 pyrazinyl, 2,4 or S-pyrimidyl, 3 or 4 pyridazinyl, s-triazinyl, 3,4 or b-as-triazinyl (1,2,3- triazinyl; 1,3,5-Triazinyl; l ,2,4-triazinyl).
  • Preferred examples of five-membered heterocyclic ring structures containing from one to four hetero atoms are:
  • heterocyclic ring structures are the oxazole, thiazolyl and pyrole rings in that order of importance.
  • the R substituent on the heterocyclic nucleus can be in any available position and may be in one or more positions.
  • the compounds described above have anti-inflammatory activity and are effective in the prevention and inhibition of edema and granuloma tissue formation.
  • some of them have a useful degree of anti-pyretic and analgesic activity.
  • they are normally administered orally in tablets or capsules, the optimum dosage depending on the particular compound being used and the type and severity of the condition being treated.
  • oral dose levels of preferred compounds in the range of 50 mg. to 10 g. per day are useful in the control of said conditions, depending on the activity of the specific compound and the reaction sensitivity of the patient.
  • the compounds of the instant invention can be prepared by a carboxylation reaction wherein the appropriate starting material is reacted with carbon dioxide, preferably in the presence of potassium carbonate.
  • the reaction is usually carried out in a pressurized vessel at a wide range of temperatures especially from about 50 to 200 C., preferably at about 175 C. at 800 p.s.i. initial pressure. The pressure can also vary from atmospheric pressure on up.
  • the reaction mixture is carried out for a sufficient time to consume the stoimetric amount of carbon dioxide.
  • the desired product can be isolated by extraction with water, the water layer then acidified and the precipitated product recrystallized.
  • EXAMPLE 1 EXAMPLE Preparation of 4-(2-oxazolyl-salicylic acid A. m-(Diethoxy ethylaminomethyl)-nitrobenzene 22.7 Gms. (0.15 moles) of 3-nitro-benzaldehyde and 20.0 gms. (0.15 moles) of diethoxyethyl amine were mixed together and heated in an oil bath for about 1 hour until no more water is given off. The mixture was then cooled and diluted with an ether-hexane mixture at which time a solid material crystallized. The solid material was filtered and dried yielding 34.3 gms. of m- (diethoxy ethylaminomethyl)-nitrobenzene, m.p.
  • This solid was a boron complex of 2-chloro-4-(mhydroxyphenyl)-thiazole. It was decomposed by heating it with a saturated sodium bicarbonate solution for about one-half hour on a steam bath. The crude solid was filtered, dried and crystallized from petroleum ether. A yield of 0.9 g. of 2-chloro-4-(m-hydroxyphenyl)-thiazole was obtained, n1.p. 89-90 C. D. 4-[4-(2-chlorotl'iiazolyl)]-salicylic acid 2,3 gms. of 2-chloro-4-( m-hydroxyphenyl)-thiazole and 5.1 gms.
  • R is hydrogen, lower alkyl, lower alkoxy, halogen or haloloweralkyl
  • R is hydrogen, lower alkyl, halo, amino, lower alkylamino, di( lower a1kyl)amino, hydroxy or lower alkoxy.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

New salicyclic acid compounds, particularly 4-(heterocyclic)salicylic acid derivatives and process for their preparation are claimed. The new 4-(heterocyclic)salicyclic acid compounds described have anti-inflammatory, anti-pyretic and analgesic activity.

Description

United States Patent Shen et al. Aug. 29, 1972 [54] 4-(PYRROLYL)-SALICYLIC ACID A, 260/347.3, 424/232 DERIVATIVES [51] Int. Cl. ..C07d 27/20 [72] inventors: Tsung Ying She, westfield; [58] Field of Search ..260/326.3
goIward Jones, l-lolmdel, 60th of Prim Examiner Alex Maze] Assistant ExaminerJoseph A. Narcavage [73] Assignee: Merck & Co,, Inc,, Rahway, NJ, AttorneyMichael C. Sudol, J12, Harry E. Westlake,
. Jr. and I. Louis Wolk [22] Filed: June 22, 1970 21 Appl. No.: 48,479 1 ABSTRACT New salicyclic acid compounds, particularly 4- [52] C] 260]3263260250R 260,250 A (heterocyclic)-salicylic acid derivatives and process 260/251 R, 260/256.4 R, 260/256.4 C, 260/290 R, 260/296 R, 260/297 R, 260/302 R, 260/302 D, 260/306.8 R, 260/306.8 D, 260/307 R, 260/307 H, 260/309, 260/332.2
for their preparation are claimed. The new 4-(hetero cyclic)salicyclic acid compounds described have antiinflammatory, anti-pyretic and analgesic activity.
3 Claims, No Drawings 1 4-(PYRROLYL)-SALICYLIC ACID DERIVATIVES BACKGROUND OF THE INVENTION The development of anti-inflammatory compounds in the past two decades has seen the growth of a great many new drugs. Most of these have been steroids of the ll-oxygenated pregnane series. These, while highly effective, have the drawback of causing many side effects. There is a need in the market for equally effective compounds of much simpler structure and having less side effects.
SUMMARY OF THEINVENTION DESCRIPTION AND PREFERRED EMBODIMENTS This invention relates to new heterocyclic phenyl compounds and to processes for producing the same. More specifically, it relates to 4-(heterocyclic)-salicylic acid compounds (2-hdroxy -4-heterocyclic benzoic acids). Still more specifically, this invention relates to compounds having the following general formula:
R2 R1 H COOH wherein Het is a 6- membered ring structure containing from one to three hetero atoms or a five-membered ring structure containing from one to four hetero atoms. The hetero atoms are either nitrogen, sulphur, or oxygen;
R, is hydrogen, lower alkyl, lower alkoxy, halogen, or
halo lower alkyl;
R; is hydrogen, alkyl (preferably lower alkyl, such as methyl, ethyl, propyl, isopropyl, butyl or pentyl), halo (such as, chlorine, bromine or iodine or fluorine), amino, alkyl amino, (preferably lower alkyl amino, such as methyl amino or isopropyl amino), dialkyl amino, (preferably diloweralkyl amino such as dimethyl amino or diethyl amino), hydroxy or alkoxy (preferably lower alkoxy, such as methoxy or ethoxy).
Preferable examples of the six-membered ring structure containing from one to three hetero atoms are 2,3 or 4-pyridyl, 2 or 3 pyrazinyl, 2,4 or S-pyrimidyl, 3 or 4 pyridazinyl, s-triazinyl, 3,4 or b-as-triazinyl (1,2,3- triazinyl; 1,3,5-Triazinyl; l ,2,4-triazinyl).
Preferred examples of five-membered heterocyclic ring structures containing from one to four hetero atoms are:
2 or 3 furyl,
2 or 3 thienyl,
2,4 or S-thiazolyl,
3 or 4(B 1,2,5-thiadiazolyl),
2 or5-( 1,3,4-thiadiazolyl),
3 or 5-(-B (1,2,4-thiadiazolyl),
2,4 or 5-oxazolyl,
3,4 or 5-isooxazolyl,
1,2 or 3-pyrrolyl,
1,2 or 4-imidazolyl.
The most preferred heterocyclic ring structures are the oxazole, thiazolyl and pyrole rings in that order of importance.
In all the above structures, the R substituent on the heterocyclic nucleus can be in any available position and may be in one or more positions.
Representative compounds of this invention are as follows:
4( N-pyrrolyl)-salicylic acid,
4-((2-oxazolyl)-selicylic acid,
4-( 2-thienyl)-salicylic acid,
4-(2-pyridyl)-salicylic acid,
4-( 3-pyridyl)-salicylic acid,
2-hydroxy-4-(4'-pyrimidyl)-benzoic acid,
3-hydroxy-4-(2'-thiazolyl)-benzoic acid.
We have found that the compounds described above have anti-inflammatory activity and are effective in the prevention and inhibition of edema and granuloma tissue formation. In addition, some of them have a useful degree of anti-pyretic and analgesic activity. For these purposes, they are normally administered orally in tablets or capsules, the optimum dosage depending on the particular compound being used and the type and severity of the condition being treated. Although the optimum quantities to be used will depend on the compound employed and the particular type of disease treated, oral dose levels of preferred compounds in the range of 50 mg. to 10 g. per day are useful in the control of said conditions, depending on the activity of the specific compound and the reaction sensitivity of the patient.
The compounds of the instant invention can be prepared by a carboxylation reaction wherein the appropriate starting material is reacted with carbon dioxide, preferably in the presence of potassium carbonate. The reaction is usually carried out in a pressurized vessel at a wide range of temperatures especially from about 50 to 200 C., preferably at about 175 C. at 800 p.s.i. initial pressure. The pressure can also vary from atmospheric pressure on up. The reaction mixture is carried out for a sufficient time to consume the stoimetric amount of carbon dioxide. When the reaction is complete, the desired product can be isolated by extraction with water, the water layer then acidified and the precipitated product recrystallized.
Various other methods for preparing the end products 'are shown in the following examples. Also, the following examples should be construed as illustrations of the invention and not limitations thereof.
EXAMPLE 1 EXAMPLE Preparation of 4-(2-oxazolyl-salicylic acid A. m-(Diethoxy ethylaminomethyl)-nitrobenzene 22.7 Gms. (0.15 moles) of 3-nitro-benzaldehyde and 20.0 gms. (0.15 moles) of diethoxyethyl amine were mixed together and heated in an oil bath for about 1 hour until no more water is given off. The mixture was then cooled and diluted with an ether-hexane mixture at which time a solid material crystallized. The solid material was filtered and dried yielding 34.3 gms. of m- (diethoxy ethylaminomethyl)-nitrobenzene, m.p. 4244 C. B. m-(2'-Oxazolyl)-nitrobenzene A mixture of 65 of phosphorus pentoxide and 20 ml. of concentrated sulfuric acid was added to a threenecked flask, and the mixture heated to 185-190 C. To this mixture was added another mixture composed of 175 gms. of m-(diethoxy ehtylaminomethyl) nitrobenzene, dissolved in 175ml. of cold concentrated sulfuric acid. The entire mixture was then refluxed at 190 C. for approximately one-half hour. The mixture was cooled and poured onto ice, at which time a solid precipitated. The solid was filtered and recrystallized from an ethanol-water mixture to yield approximately 4.5 gms. of m-(2-oxazolyl)-nitrobenzene, m.p. 9295 C C. 2-(m-Aminophenyl)-oxazole 2.5 Gms. of m-(2-oxazolyl)-nitrobenzene was added in a hydrogenation bomb to 0.5 gm. of percent pal ladium on carbon and 250 ml. of ethyl alcohol. Hydrogen gas was added under pressure until the uptake was complete. The reaction mixture was then filtered and the filtrate concentrated to dryness to yield 2.2 gms. of 2-(m-aminophenyl)-oxazole, m.p. 66.06 5.5C. D. 2-(m-Hydroxyphenyl)-oxazole A solution of 390 ml. (2.44 moles) of 2-(maminophenyl)-oxazole in 10 ml. of 2N sulfuric acid was prepared and cooled in an ice bath. To this mixture was added a solution of 190 ml. (2.75 moles) of sodium nitrite in 2 ml. of water. The reaction mixture was stirred at room temperature for 10 minutes and then in 55 C. for 0.5 hour and finally at room temperature overnight. The reaction mixture was then extracted with ethylene dichloride, the ethylene dichloride separated, dried with magnesium sulfate, and concentrated to yield a crude solid. The crude solid was recrystallized from an ethylene dichloride-hexane solvent and yielded substantially pure Z-(m-hydroxyphenyl)-oxazole. E. 4-(2-Oxazolyl)-salicylic acid 480 mg. of 2-(m-hydroxyphenyl)-oxazole and 1.7 gms. of potassium carbonate were ground together and dried overnight at 60 C. under high vacuum. The mixture was subjected to 4,500 p.s.i. of carbon dioxide in a glass tube in a pressure bomb. The temperature was raised to 250 for 6 hours. After cooling and venting the contents of the bomb are taken up in 100 ml. of water and filtered. Hydrochloric acid was added to give a precipitate which was collected and dried in a vacuum oven. The precipitate recrystallized from an ethanol-water mixture to yield 4-(2-oxazolyl)-salicylic acid, m.p. 255-25 8 C.
EXAMPLE 3 Preparation of 4-(2-thiazolyl)-salicylic acid A. m-Cyanoanisole 25 Gms. of m-cyanophenol, 30 gms. of dimethyl sulfate, and 155 ml. of 2N sodium hydroxide were stirred at room temperature for 1 hour. The mixture was extracted with two 150 m1. portions of ethyl ether. The ether layer was then washed with water, dried and evaporated to yield m-cyanoanisole as a colorless oil. B. 3-Methoxyben2ylthioamide 19.0 Gms. of m-cyanoanisole and 22 gms. of thioacetarnide were dissolved in ml. of dimethyl formamide. The reaction mixture was stirred while hydrogen chloride gas was bubbled in. During the addition of the hydrogen chloride gas, the color of the reaction mixture went from pale yellow to dark red. After 20 minutes, the reaction mixture was heated on a steam bath for 20 minutes more, cooled and poured into 150 mol. of water. The mixture was extracted with three 100 ml. portions of ethyl ether. The ether mixture was washed with water and the ether then evaporated to yield 20.5 gms. of 3-methoxybenzylthioamide as a dark red oil. C. 3-(2-Thiazolyl)-anisole 20.5 gms. of 3-methoxybenzylthioamide and 24.6 gms. of B-bromoacetaldehyde diethylacetol were mixed together and dissolved in percent ethyl alcohol with 5 ml. of concentrated hydrochloric acid. The mixture was refluxed for 3 hours and cooled, at which time pale yellow needles crystallized out. These crystals were filtered and the solid dried at 70 C. under vacuum for 3 hours. A yield of 14.2 gms. of 3-(2- thiazolyl)-anisole thiazolyl)-anisole resulted, m.p. 200-202 C. D. 3-(2-Thiazolyl)-phenol 14.0 Gms. 3-(2-'lhiazolyl)-phenol 3-(b 2-thiazolyl)- anisole was added to 63ml. of 48 percent hydrobromic acid and the mixture refluxed for 2 hours. The reaction mixture was then cooled in an ice bath, basified by the addition of sodium bicarbonate and again cooled. The solid precipitate which formed was filtered and dried to yield 2.1 gms. of 3-(2-thiazolyl)-phenol, m.p. 137142 C. E. 4-(b 2-Thiazolyl)-salicylic acid 5.6 gms. of 3-(2-thiazolyl)-phenol and 12.0 gms. of potassium'carbonate were subjected to 4,700 p.s.i. of carbon dioxide in a glass tube in a pressure bomb at 180 for 6 hours. After cooling and venting the contents of the bomb are taken up in ml. of boiling water and filtered. Hydrochloric acid was added and the precipitate filtered. The solid was then dried in an oven to yield 1.2 gms. of 4-(2-thiazolyl-salicylic acid, m.p. 247250 C.
EXAMPLE 4 Preparation of 4-[4-( 2-chlorothiazolyl)]-salicylic acid A. a-Thiacyanato-m-methoxyacetophenone A hot saturated solution of potassium thiocyanato (43.5 gms.) in 30 ml. of water was added to a warm 500 ml. solution of 50.0 gms. of m-methoxyphenacyl bromide. The reaction mixture was allowed 50.0 stand at room temperature for 3 hours. The mixture was poured into 1 l. of water and the undissolved solid was filtered and dried. There was obtained 43.0 gms. of athiocanato-m-methoxyacetophenone, m.p. 6870 C. B. 3-Chloro-4-((m-methoxyphenyl)-thiazole Hydrogen chloride gas was bubbled into a suspension of 5.0 gms. of a-thiocyanato-m-methyoxyacetophenone in 200 ml. of ether, the reaction mixture being cooled in an ice bath during the 1.5 hours. After about 45 minutes, solution was effected and after another -25 minutes a precipitate started to form. The precipitate was filtered and decomposed to the parent thiazole by stirring for a few minutes in a dilute sodium carbonate solution. In this way the crude hydrochloride salt of 2-chloro-4-(m-methoxyphenyl)- thiazole was obtained, m.p. 64-68 C. C. 2-Chloro-4-(m-hydroxyphenyl )-thiazole 5.0 gms. of boron tribromide was added to a suspension of 2.0 gms. of 2-chloro-4-(m-methoxyphenyl)- thiazole in ml. of methylene dichloride. The reaction mixture was stirred at room temperature for 6 hours. Water was added to the reaction mixture and a white solid (1,8 gms.) precipitated, m.p. 150160C.
This solid was a boron complex of 2-chloro-4-(mhydroxyphenyl)-thiazole. It was decomposed by heating it with a saturated sodium bicarbonate solution for about one-half hour on a steam bath. The crude solid was filtered, dried and crystallized from petroleum ether. A yield of 0.9 g. of 2-chloro-4-(m-hydroxyphenyl)-thiazole was obtained, n1.p. 89-90 C. D. 4-[4-(2-chlorotl'iiazolyl)]-salicylic acid 2,3 gms. of 2-chloro-4-( m-hydroxyphenyl)-thiazole and 5.1 gms. of potassium carbonate were subjected to a pressure of 4,0005,000p.s.i. of carbon dioxide at 175 C. for 8 hours. The 85 was vented and the crude product added to 100 ml. of water on the steam bath, a brown oil separated. The supernantent liquid was decanted off. The brown residue solidified at room temperature and was sublimed at 200 C. 85mg. of 4-[4-(2- chlorothiazolyl)]-salicylic acid was obtained, m.p. l85-1 86 C.
EXAMPLE 5 Preparation of 4-(4-thiazolyl)-salicylic acid A. 4-(m-Methoxyphenyl )-thiazole 5.78 gms. of 2'chloro-4-(-methoxyphenyl)-thiazole, 5.0 gms. of palladium on carbon, 200 ml. of methanol,
and 20 ml. of 10 percent sodium hydrochloric acid were put into a hydrogen bomb and the reaction mixture hydrogenated at room temperature and 30 p.s.i. hydrogen pressure until the uptake of hydrogen ceases. The palladium catalyst was filtered off and the filtrate concentrated to 25 ml. and diluted with 50 ml. of water and an amber oil separated. The oil was extracted with ether, dried, and concentrated down to give 3.0 gms. of 4-(m-methoxyphenyl)-thiazole as an amber oil. B. 4-(m-Hydroxyphenyl)-thiazole 3.0 gms. of 4-(m-methoxyphenyl-)-thiazole was added to 10 ml. of concentrated hydrochloric bromic acid and the mixture refluxed for 5 hours. Upon cooling a solid appeared, which was filtered. The solid was taken up in dilute sodium hydroxide and neutralized. The solid precipitate which appeared was filtered and recrystallized from chloroform to yield 2.1 gms. of 4- (m-hydroxyphenyl)-thiazole, m.p. 1 l8l20 C.
C. 4-(4-Thiazolyl)-salicylic acid 2.1 gms. of 4-(m-hydroxyphenyl)-th1azole was added R2 R fill 400. kJ
wherein is pyrrolyl;
R is hydrogen, lower alkyl, lower alkoxy, halogen or haloloweralkyl; and
R is hydrogen, lower alkyl, halo, amino, lower alkylamino, di( lower a1kyl)amino, hydroxy or lower alkoxy.
2. The compound of claim 1, wherein R and R are hydrogen.
3. The compound 4-N-pyrrolyl-salicylic acid.

Claims (2)

  1. 2. The compound of claim 1, wherein R1 and R2 are hydrogen.
  2. 3. The compound 4-N-pyrrolyl-salicylic acid.
US48479A 1970-06-22 1970-06-22 4-(pyrrolyl)-salicylic acid derivatives Expired - Lifetime US3687971A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4847970A 1970-06-22 1970-06-22

Publications (1)

Publication Number Publication Date
US3687971A true US3687971A (en) 1972-08-29

Family

ID=21954809

Family Applications (1)

Application Number Title Priority Date Filing Date
US48479A Expired - Lifetime US3687971A (en) 1970-06-22 1970-06-22 4-(pyrrolyl)-salicylic acid derivatives

Country Status (6)

Country Link
US (1) US3687971A (en)
CA (1) CA952116A (en)
DE (1) DE2130709A1 (en)
FR (1) FR2100810B1 (en)
GB (1) GB1295570A (en)
NL (1) NL7107784A (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3878225A (en) * 1973-03-01 1975-04-15 Hoechst Co American Condensed pyrroles bearing an N-phenyl substituent
US3904761A (en) * 1974-01-25 1975-09-09 Hoechst Co American Method of preventing thrombosis
US3931407A (en) * 1973-03-01 1976-01-06 American Hoechst Corporation Method of treatment with and compositions containing condensed pyrroles bearing an N-phenyl substituent
US4111935A (en) * 1975-01-02 1978-09-05 Smith Kline & French Laboratories Limited 3-chloro-6-phenylpyridazine compounds
US4122275A (en) * 1977-08-08 1978-10-24 American Cyanamid Company Imidazolinyl benzamides as herbicidal agents
US4166911A (en) * 1977-02-02 1979-09-04 Farmitalia Carlo Erba S.P.A. Pyridazinyl-ergoline compounds having neuroleptic activity
US4242351A (en) * 1979-05-07 1980-12-30 Imperial Chemical Industries Limited Antisecretory oxadiazoles and pharmaceutical compositions containing them
US5208251A (en) * 1986-05-09 1993-05-04 Warner-Lambert Company Styryl pyrazoles, isoxazoles and analogs thereof having activity as 5-lipoxygenase inhibitors, pharmaceutical compositions and methods of use therefor
US20040116427A1 (en) * 2002-11-21 2004-06-17 New York Blood Center Compounds for inhibition of HIV infection by blocking HIV entry

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL55064A (en) * 1977-08-08 1983-06-15 American Cyanamid Co 5,5-disubstituted-4-oxo-2-imidazolin-2-yl benzoic acid esters,their preparation and herbicidal compositions comprising them
AU2006228690A1 (en) 2005-03-31 2006-10-05 Ucb Pharma S.A. Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3185689A (en) * 1965-05-25 Tolyl-x-(jh)-pyrimidones
DE896047C (en) * 1951-09-12 1953-11-09 Basf Ag Process for the preparation of salicylic acid derivatives
NL6515006A (en) * 1964-11-27 1966-05-31
US3558641A (en) * 1967-10-06 1971-01-26 Merck & Co Inc Certain pyridyl salicylic acid derivatives

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3878225A (en) * 1973-03-01 1975-04-15 Hoechst Co American Condensed pyrroles bearing an N-phenyl substituent
US3931407A (en) * 1973-03-01 1976-01-06 American Hoechst Corporation Method of treatment with and compositions containing condensed pyrroles bearing an N-phenyl substituent
US3904761A (en) * 1974-01-25 1975-09-09 Hoechst Co American Method of preventing thrombosis
US4111935A (en) * 1975-01-02 1978-09-05 Smith Kline & French Laboratories Limited 3-chloro-6-phenylpyridazine compounds
US4166911A (en) * 1977-02-02 1979-09-04 Farmitalia Carlo Erba S.P.A. Pyridazinyl-ergoline compounds having neuroleptic activity
US4252948A (en) * 1977-02-02 1981-02-24 Farmitalia Carlo Erba S.P.A. Ergoline derivatives
US4122275A (en) * 1977-08-08 1978-10-24 American Cyanamid Company Imidazolinyl benzamides as herbicidal agents
US4242351A (en) * 1979-05-07 1980-12-30 Imperial Chemical Industries Limited Antisecretory oxadiazoles and pharmaceutical compositions containing them
US5208251A (en) * 1986-05-09 1993-05-04 Warner-Lambert Company Styryl pyrazoles, isoxazoles and analogs thereof having activity as 5-lipoxygenase inhibitors, pharmaceutical compositions and methods of use therefor
US20040116427A1 (en) * 2002-11-21 2004-06-17 New York Blood Center Compounds for inhibition of HIV infection by blocking HIV entry
US7241803B2 (en) * 2002-11-21 2007-07-10 New York Blood Center Compounds for inhibition of HIV infection by blocking HIV entry
US20070232684A1 (en) * 2002-11-21 2007-10-04 New York Blood Center Compounds for inhibition of HIV infection by blocking HIV entry

Also Published As

Publication number Publication date
FR2100810A1 (en) 1972-03-24
CA952116A (en) 1974-07-30
FR2100810B1 (en) 1975-06-06
NL7107784A (en) 1971-12-24
DE2130709A1 (en) 1971-12-23
GB1295570A (en) 1972-11-08

Similar Documents

Publication Publication Date Title
JPS582936B2 (en) 5↓-Production method of aroylpyrroleacetic acid and its salts
US3687971A (en) 4-(pyrrolyl)-salicylic acid derivatives
US3784697A (en) Pharmaceutical composition containing phenoxyalkane-carboxylic acids,salts and esters thereof
US3558641A (en) Certain pyridyl salicylic acid derivatives
JP2004359676A (en) Substituted thiazolidinedione derivatives
WO2005108370A1 (en) Benzene compounds
US3624103A (en) 3-indoleacetohydroxamic acids
JPS62500872A (en) Novel azo compound
US3673212A (en) Substituted phenylacetic acids and esters thereof
US3966966A (en) Pharmaceutical compositions and method of treatment employing 1,3-dioxo-2,2-disubstituted indanyloxy alkanoic acids
US3976681A (en) [1,3-Dioxo-2-substituted and 2,2-disubstituted- indanyloxy (or thio] alkanoic acids
US4173577A (en) Phenylacetohydroxamic acids
Milas Catalytic oxidations in aqueous solutions I. The oxidation of furfural
US3631177A (en) 3-phenacyl-2-oxoindolines
JPS5830302B2 (en) Shinki Hōkōzoku Carbon Sanamide Yudōtai no Seizō Hōhō
US3929833A (en) Organic compounds
Brookes et al. 194. Chemistry of micrococcin P. Part III
US3812151A (en) Beta-(2,4,6-triiodo-3-acetamidinophenyl)-propionic acids
US2965646A (en) Pyrtoylmethyldibenzylamines
IL31915A (en) Thiazolines,their preparation and pharmaceutical compositions containing them
US3676451A (en) Thiazolylsalicylic acids
JPS60104084A (en) 4h-benzo(4,5)cyclohepta(1,2-b)thiophene derivative
US3843671A (en) 5-(oxazolyl)-and 5-(thienyl)-salicyclic acids
US2485152A (en) Ester of nicotinic acid
WENNER et al. DERIVATIVES OF 2-PYRIDONE